Literature DB >> 11176264

Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus.

D Klein1, C M Leutenegger, C Bahula, P Gold, R Hofmann-Lehmann, B Salmons, H Lutz, W H Gunzburg.   

Abstract

Determination of retroviral load is an important tool in the investigation of the success of therapeutic or vaccination trials in patients infected with lentiviruses such as HIV, or with their simian (SIV) or feline (FIV) counterparts. We have developed an one-tube quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assay based on the ABI Prism 7700 Sequence Detection System (TaqMan) to quantify the viral load of FIV-infected cats. Two different primer/probe systems were designed to detect a broad range of clade A FIV isolates. Both systems are characterized by excellent reproducibility, high sensitivity, and a wide range of quantification. As a consequence of this improved precision in the quantitative RT-PCR, preassay variations have greater impact on the accuracy of the viral load estimation. To compensate for these variations, we improved the assay and developed a multiplex real-time RT-PCR, which allows simultaneous calculation of the viral copy number and the individual recovery rate in an one-tube reaction. This enables the rapid and accurate calculation of copy number independent of preassay variations. In further studies, two additional real-time RT-PCR assays were designed and used to investigate the influence of sequence variations in the binding regions for either the primers or probe. Sequence mismatches in this region had a significant effect (up to 4 logarithmic decades) on reaction efficiency. In view of the inherent variability of retroviral sequences, these results underline the necessity to check reaction efficiencies before determining viral load.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176264     DOI: 10.1097/00126334-200101010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements.

Authors:  Juraj Hlavaty; Anika Stracke; Dieter Klein; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  The effect of primer-template mismatches on the detection and quantification of nucleic acids using the 5' nuclease assay.

Authors:  Ralph Stadhouders; Suzan D Pas; Jeer Anber; Jolanda Voermans; Ted H M Mes; Martin Schutten
Journal:  J Mol Diagn       Date:  2009-11-30       Impact factor: 5.568

4.  Methamphetamine and lentivirus interactions: reciprocal enhancement of central nervous system disease.

Authors:  Salvador Huitron-Resendiz; Steven J Henriksen; Margaret C Barr; Maria P Testa; Elena Crawford; Loren H Parsons; Manuel Sanchez-Alavez; Tom R Phillips
Journal:  J Neurovirol       Date:  2010-07       Impact factor: 2.643

5.  Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.

Authors:  Margaret J Hosie; Brian J Willett; Dieter Klein; Thomas H Dunsford; Celia Cannon; Masayuki Shimojima; James C Neil; Oswald Jarrett
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues.

Authors:  Yoshinori Ito; Jean-Charles Grivel; Leonid Margolis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3.

Authors:  Salvador Huitron-Resendiz; Sohela De Rozières; Manuel Sanchez-Alavez; Bernd Bühler; Ying-Chuan Lin; Danica L Lerner; Nicholas W Henriksen; Mboya Burudi; Howard S Fox; Bruce E Torbett; Steven Henriksen; John H Elder
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity.

Authors:  Malou C Gemeniano; Earl T Sawai; Christian M Leutenegger; Ellen E Sparger
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Molecular Investigations of Rickettsia helvetica infection in dogs, foxes, humans, and Ixodes ticks.

Authors:  Felicitas S Boretti; Andrea Perreten; Marina L Meli; Valentino Cattori; Barbara Willi; Nicole Wengi; Sándor Hornok; Hanspeter Honegger; Daniel Hegglin; Roman Woelfel; Claudia E Reusch; Hans Lutz; Regina Hofmann-Lehmann
Journal:  Appl Environ Microbiol       Date:  2009-03-27       Impact factor: 4.792

10.  Development and application of a quantitative real-time PCR assay to detect feline leukemia virus RNA.

Authors:  Andrea N Torres; Kevin P O'Halloran; Laurie J Larson; Ronald D Schultz; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.